Sermorelin and CJC-1295 Compared

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

CJC-1295 vs. Sermorelin: Key Insights for 2024

Sermorelin and CJC-1295 are both derivatives of growth hormone–releasing hormone (GHRH). Because they share a common origin, they exhibit overlapping biological functions. However, their structural modifications create distinct differences that significantly impact their pharmacology and clinical application. Understanding these differences is critical to determining which compound may be more suitable for a given research or therapeutic context.

Structural Comparison

Sermorelin

• Structure: GHRH fragment 1–29
• Sequence: Tyr-Ala-Asp-Ala-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Met-Ser-Arg
• Molecular Formula: C149H246N44O42S
• Molecular Weight: ~3358 g/mol

CJC-1295

• Structure: Modified GHRH fragment 1–29 with substitutions to improve stability
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
• Molecular Formula: C152H252N44O42
• Molecular Weight: ~3368 g/mol

Sermorelin is often referred to as GRF (1-29), representing the biologically active core of GHRH. CJC-1295, by contrast, incorporates specific amino acid substitutions designed to increase resistance to enzymatic breakdown. These modifications slow its clearance from the body and extend its half-life.

Pharmacokinetics and Half-Life

• Sermorelin: Approximate half-life of 5 minutes, due to rapid enzymatic degradation and renal clearance.
• CJC-1295: Modified to resist enzymatic cleavage, with an extended half-life of ~30 minutes in its base form.

When further modified with a Drug Affinity Complex (DAC), CJC-1295 binds to plasma proteins (notably albumin), prolonging circulation time to several days. This allows for much less frequent dosing compared to sermorelin.

The DAC Debate

A common point of discussion is whether “CJC-1295” should be defined only as the DAC-modified version or if it can also refer to the unmodified mod GRF (1-29). Historically, the original designation included DAC. Today, researchers typically specify “CJC-1295 with DAC” to avoid ambiguity.

Growth Hormone Secretion Dynamics

Both sermorelin and CJC-1295 stimulate the anterior pituitary by activating the GHRH receptor, thereby promoting pulsatile secretion of growth hormone (GH).

• Sermorelin mimics natural physiology more closely, as its rapid clearance preserves the sharp peaks and valleys of GH secretion.
• CJC-1295 extends the duration of elevated GH levels, transforming sharp peaks into broader plateaus. This amplifies overall GH exposure but slightly alters the body’s natural rhythm of secretion.

In essence:

• Sermorelin = more physiologic, shorter-acting, natural pulse enhancer.
• CJC-1295 = longer-acting, sustained GH elevation, potentially stronger cumulative effects.

Both sermorelin and CJC-1295 are effective GHRH analogues, but their key differences lie in duration of action and impact on GH secretion patterns.

• For researchers prioritizing a natural replication of GH pulsatility, sermorelin may be the preferred model.
• For studies requiring extended GH elevation and reduced dosing frequency, CJC-1295—especially with DAC—offers a compelling alternative.
  

Read More:  sermorelin vs hgh 

Product available for research use only: